Syndax Pharmaceuticals has announced a new collaboration with Roche’s Genentech unit dedicated to combining small molecule cancer drug entinostat with the latter’s immunotherapy, Tecentriq.

Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

Overview of the Recent Trade On September 30, 2024, State Street Corp made a significant addition to its investment portfolio ...

In this work, Kamal, Knox et al develop a high-throughput system to identify small molecules that disrupt amyloid formation by pre-selecting compounds that suppress molecular interactions within ...

Barclays analyst Peter Lawson assigned a Buy rating to Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Neckers, Jeremy L. Davis, Choung D. Hoang, Jonathan M. Hernandez, David S. Schrump, R. Taylor Ripley. Induction of Thioredoxin-Interacting Protein by the Histone Deacetylase Inhibitor, Entinostat, ...